New Stock News | Bonasia's Hong Kong IPO Prospectus Invalidated
Bonasia (Hangzhou) Pharmaceutical Technology Co., Ltd. (short name: Bonasia) submitted its Hong Kong stock offering prospectus on February 11, 2026, which will expire 6 months later on August 11, 2026.
Bonasia (Hangzhou) Pharmaceutical Technology Co., Ltd. (abbreviated as Bonasia) submitted its Hong Kong IPO prospectus on February 11, 2026, which will expire six months later on August 11, 2026. At the time of submission, CISI FIN and ICBC International were its joint sponsors.
According to the previously disclosed prospectus, Bonasia is a clinical contract research organization (CRO) headquartered in Hangzhou, China, dedicated to empowering innovative drug clinical research through digitization. The company's core business is to provide clinical trial technical services for pharmaceutical and biotechnology companies both domestically and internationally, aiming to accelerate the R&D and commercialization processes of chemical drugs and biological products.
Related Articles
China Securities Co., Ltd.: Yushu's IPO pricing exceeded expectations and is expected to drive a reshaping of valuations for the parent manufacturers.
Positive Results from Mid-term Trial of ABCL635 for Hyperhidrosis Treatment, AbCellera Biologics (ABCL.US) Soars.
Hong Kong Stock Concept Tracking | The 14th Five-Year Plan Officially Launched, Coal Industry Welcomes a Valuation Rebuilding Turning Point (with Related Stocks)
China Securities Co., Ltd.: Yushu's IPO pricing exceeded expectations and is expected to drive a reshaping of valuations for the parent manufacturers.
Positive Results from Mid-term Trial of ABCL635 for Hyperhidrosis Treatment, AbCellera Biologics (ABCL.US) Soars.
Hong Kong Stock Concept Tracking | The 14th Five-Year Plan Officially Launched, Coal Industry Welcomes a Valuation Rebuilding Turning Point (with Related Stocks)
RECOMMEND
